Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171535 | 0.82 | PDE10A (0.50) | PDE10AHPGDSLMNASMN1; SMN2POLB | |
| SCHEMBL16466775 | 0.81 | OPRK1 (0.44) | OPRK1LMNASMN1; SMN2 | |
| SCHEMBL24970193 | 0.75 | HRH4 (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL4159979 | 0.74 | PDE10A (0.43) | PDE10AHPGDSLMNASMN1; SMN2 | |
| SCHEMBL4195075 | 0.73 | PDE10A (0.54) | PDE10AHPGDSOPRK1LMNASMN1; SMN2 | |
| SCHEMBL25925616 | 0.72 | ALDH1A1 (0.44) | PDE10AOPRK1SMN1; SMN2POLB | |
| SCHEMBL898877 | 0.72 | CHRNB2 (0.50) | — | |
| SCHEMBL18483777 | 0.72 | PLAU (0.39) | OPRK1POLB | |
| SCHEMBL18837988 | 0.72 | MEN1 (0.53) | LMNASMN1; SMN2POLB | |
| SCHEMBL16467124 | 0.71 | PDE10A (0.51) | PDE10AHPGDSOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062291-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009029214-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009025839-A2 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062291-A1 | PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | PDE10A 1/4885HPGDS 3364/4885OPRK1 1089/4885 |
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE4A, PDE4B | PDE10A 8/4885HPGDS 2513/4885OPRK1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.